Vertex Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Vertex Pharmaceuticals Inc Unternehmen

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Vertex Pharmaceuticals Inc Informationen



BörsenkürzelVRTX

Name des UnternehmensVertex Pharmaceuticals Inc

IPO-datumJul 24, 1991

CEOKewalramani (Reshma)

Anzahl der mitarbeiter6100

WertpapierartOrdinary Share

GeschäftsjahresendeJul 24

Addresse50 Northern Avenue

StadtBOSTON

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl02210

Telefon16173416393

Websitehttps://www.vrtx.com/

BörsenkürzelVRTX

IPO-datumJul 24, 1991

CEOKewalramani (Reshma)

Führungskräfte von Vertex Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

47.80K

+28.61%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

--

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

35.24K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

29.50K

+12.65%

Ms. Joy Liu

Corporate Secretary

20.73K

-5.33%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

17.74K

-112.72%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

13.66K

-78.45%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.92K

+12.69%

Ms. Jennifer J. Schneider

Independent Director

1.39K

-23.24%

Mr. Michel Lagarde

Independent Director

1.13K

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

47.80K

+28.61%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

--

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

35.24K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

29.50K

+12.65%

Ms. Joy Liu

Corporate Secretary

20.73K

-5.33%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

17.74K

-112.72%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

TRIKAFTA

10.31B

86.15%

ALYFTREK

837.80M

7.00%

Other CF products

820.10M

6.85%

Nach RegionUSD

Name

Umsatz

Anteil

United States

7.55B

63.06%

Europe

3.46B

28.91%

Other

992.40M

8.29%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

TRIKAFTA

10.31B

86.15%

ALYFTREK

837.80M

7.00%

Other CF products

820.10M

6.85%

Aktionärsstatistik

Aktualisiert: Sun, May 10

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Capital World Investors

10.05%

Capital Research Global Investors

6.82%

Vanguard Capital Management, LLC

6.51%

BlackRock Institutional Trust Company, N.A.

6.00%

State Street Investment Management (US)

4.61%

Andere

66.01%

Aktionäre

Anteil

Capital World Investors

10.05%

Capital Research Global Investors

6.82%

Vanguard Capital Management, LLC

6.51%

BlackRock Institutional Trust Company, N.A.

6.00%

State Street Investment Management (US)

4.61%

Andere

66.01%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

60.15%

Investment Advisor/Hedge Fund

28.02%

Pension Fund

2.27%

Research Firm

2.19%

Bank and Trust

2.05%

Sovereign Wealth Fund

1.33%

Hedge Fund

1.27%

Individual Investor

0.17%

Insurance Company

0.08%

Andere

2.47%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

3075

247.47M

97.50%

-4.59M

2025Q4

2995

248.62M

97.99%

-4.56M

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Capital World Investors

25.51M

10.04%

-400.40K

-1.55%

Dec 31, 2025

Capital Research Global Investors

17.32M

6.82%

+763.06K

+4.61%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

15.24M

6%

+768.21K

+5.31%

Dec 31, 2025

State Street Investment Management (US)

11.69M

4.6%

+83.54K

+0.72%

Dec 31, 2025

Geode Capital Management, L.L.C.

5.98M

2.35%

+8.16K

+0.14%

Dec 31, 2025

Invesco Capital Management (QQQ Trust)

5.40M

2.12%

-130.10K

-2.35%

Feb 28, 2026

Capital International Investors

4.73M

1.86%

+44.54K

+0.95%

Dec 31, 2025

JP Morgan Asset Management

4.54M

1.79%

+150.76K

+3.44%

Dec 31, 2025

Verbundene ETFs



Aktualisiert: Fri, Dec 5

Name

Anteil

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

VanEck Biotech ETF

Anteil9.71%

ProShares Ultra Nasdaq Biotechnology

Anteil8.83%

Invesco Nasdaq Biotechnology ETF

Anteil8.76%

iShares Biotechnology ETF

Anteil7.43%

Invesco Biotechnology & Genome ETF

Anteil5.35%

Natixis Loomis Sayles Focused Growth ETF

Anteil4.48%

First Trust NASDAQ Pharmaceuticals ETF

Anteil4.23%

First Trust NYSE Arca Biotechnology Index Fund

Anteil3.5%

Franklin Genomic Advancements ETF

Anteil3.33%

Simplify Health Care ETF

Anteil3.25%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten